Former News Items

The prelim. line-up for the 2024 GRC meeting is live!

We have posted the line-up for next year’s GRC on ‘Signaling by Adhesion Receptors’, to be held in Manchester, NH. Alex Dunn and Maggy Parsons vice-chair this fantastic meeting. You can now APPLY ONLINE now.

(November 2023)

GO KART!! A new p120/kaiso breast cancer signature

p120/Kaiso targets that control anoikis resistance in ILC after E-cadherin loss associate with prognosis, the ILC histiotype, invasion, and slow growing cells. i.e: typical ILC!. published in the JOURNAL OF PATHOLOGY.

(October 2023)

NUclear mechanical control of YAP in cancer

We co-author on work from the Roca-Cusachs lab showing that a laminin-Integrin β4-keratin link prevents YAP signals. Published in NATURE MATERIALS and sponsored by our H2020-FET MechanoControl.eu consortium.

(September 2023)

INAUGURAL LECTURE professorship Patrick

Patrick formally accepted his full professorship and gave his inaugural lecture called “A Tailored Intervention for Cancer (Research)” on the 21st of April. You can find the video here and the written format here.

(May 2023)

A NEW CANCER ASSOCIATED EXON IN TLN1 (TALIN)

Ben Goult’s lab a discovered a cancer associated exon in the Talin-1 gene (TLN1). Data are now published in the JOURNAL OF CELL BIOLOGY Thijs Koorman contributed to the cancer bits and bobs.

(March 2023)

SKOR1 controls breast cancer invasion

Lilian and Sandra identified a new FER kinase substrate called SKOR1 that promotes breast cancer invasion. Results are published in the JOURNAL OF CELL SCIENCE, and our image is featured on the cover!

(February 2023)

A NEW MOUSE skin and breast cancer MODEL

Eline and Thijmen published a new mouse model for inducible skin and mammary cancer in NEOPLASIA, based on conditional knockout of E-cadherin and p53 through inducible LGR6 expression.

(November 2022)

RSPO IS AN ONCOGENE IN BREAST CANCER

Eline published data in the JOURNAL OF PATHOLOGY showing that R-spondin-3 is an oncogenic driver of poorly differentiated invasive breast cancer! A fruitful collaboration with the John Hilkens group @ NKI/AvL.

(November 2022)

Id2 underpins THE IndolenCE OF LOBULAR BREAST CANCER

Them Id2 Boys Max Rätze and Thijs Koorman have figured out (well, at least in part) why ILC is a low grade disease! Work instigated by lab alumnus Robert van de Ven has culminated in a publication in ONCOGENE.

(June 2022)

FER controls the cancer endosome

Check out Sandra Tavares‘ paper in CELL REPORTS on FER kinase, its DIRECT targets, control over fast endosomal recycling, and predictive value in breast cancer

(June 2022)

uncoupling bundling and stiffness

Thijs Koorman’s LOXL3 paper is out in ONCOGENE! Based on findings from Karin Janssen we show that ductal breast cancer, in contrast to ILC, use Loxl3 to spatially stiffen the ECM for collective invasion.

(March 2022)

IDC-NST? ILC? DuctolObular? Mixed Breast cancer?

Christgen et al. are at it again! Cover art in the JOURNAL OF PATHOLOGY. E-cadherin expression as a diagnostic standard for ILC. An absolute no-brainer that should be Globally implemented!

(February 2022)

An idc-NST wannabe ILC forming tubules

P-cadherin Switching in ILC is out in Modern Pathology! We co-author on this work, showing that P-cadherin is the molecular determinant of a mixed-appearing histomorphology in ILBCs with tubular elements.

(June 2020)

the ELBCC lobsterpot COST action is alive!

Support for the ELBCC-instigated oncology task forces for ILC. See the ELBCC website and sign up if you want to join at the EU COST Portal for our action (CA19138). Follow @ELBCC on twitter using #LOBSTERPOT and #CA19138.

(October 2021)